The mechanism behind β-blockers' potential in improving diastolic function in patients with HFPEF is believed to be associated with the drugs' negative chronotropic and negative inotropic ...

Use of finerenone for heart failure with preserved ejection fraction carries a hyperkalemia risk, especially in patients with kidney disease.

However, the benefits of beta-blockers in “stiff heart” heart failure are less clear. This condition, also known as heart ...

The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY ...

The message is that an early decrease in eGFR with finerenone should not lead to stopping the medication, say HF experts.

Dr. Yulia Khodneva, MD, a primary care physician and a UAB researcher has received an award from the NIH to develop an intervention to help primary care providers in diagnosis of HFpEF, based on a ...

The guideline also states that patients with HFpEF and hypertension should have antihypertensive medications titrated to attain guideline-recommended blood pressure targets (Class I, level of ...

Research led by Professor Hai-Ling Margaret Cheng (BME) opens the door to earlier treatment and better outcomes ...

HFrEF and HFpEF accounted for 63.0% and 37.0% of patients ... and worsening HF hospitalizations in some patients, relative to medical therapy alone. Since 2022, American guidelines have given ...

Stifel initiated coverage on Cytokinetics Incorporated (NASDAQ:CYTK), noting the company’s catalyst rich one to two years.

Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing ...